Developer docs
API playgroundTry for free, no card

Search company profiles

Spark Biopharma

Full company profile

uuid00025kf

Namestring
Spark Biopharma
Legal namestring
SparkBioPharma, INC.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Spark Biopharma is a Seoul-based, privately held biopharmaceutical company founded in 2016 that discovers and develops first-in-class small-molecule therapeutics using its proprietary phenotypic drug discovery platform (pDOS). The company's discovery stack integrates three core technology layers: pDOS for molecular diversity creation, Seoul-Fluor custom-designed fluorescent probes for visualizing phenotypic changes in cellular systems, and FITGE/TS-FITGE for target identification and mechanism-of-action elucidation through in-gel fluorescence difference via thermal stability shift. Spark targets pharmaceutical and biotech customers developing therapeutics across autoimmune disease, inflammatory disease, fibrosis, Parkinson's disease, dyslipidemia, and cancer, and currently markets two research-use bioprobes — GB2-CY3 (a GLUT-specific glucose transporter dye) and SF44 (a lipid droplet visualization probe) — priced at USD 450 per 2 mg through direct website sales.

The company's business model combines three revenue streams: (i) bioprobe product sales via a direct e-commerce channel, (ii) research collaborations and licensing agreements with pharmaceutical partners including LG Chemistry, Odyssey Therapeutics, HK Inno.N, Handok, and Donga ST, and (iii) non-dilutive grant funding from Korean national programs such as KDDF and the national new drug development project. As of 2026, Spark's pipeline includes SBP-401 (FDA Orphan Drug Designation, February 2024), an HMGB1 inhibitor for idiopathic pulmonary fibrosis (Phase 2, KDDF-selected), SBP-201 for Parkinson's disease (national project-selected, December 2025), and a STING degrader program. The company is led by founder and CEO Park Seung-beom, a Seoul National University Chemistry Department professor, and is actively preparing for a KOSDAQ IPO after completing a KRW 31.5 billion pre-IPO funding round in May 2026.

Spark has raised approximately KRW 28.5 billion across disclosed rounds (Handok KRW 3 billion in November 2021, Series C KRW 25 billion in April 2022) plus the 2026 pre-IPO round, with a syndicate of Korean institutional investors including Korea Development Bank, Industrial Bank of Korea, Shinhan Capital, KB Investment, IMM Investment, and Company K Partners. With 11-50 employees and no public revenue disclosure, the company is in a clinical-stage growth phase where partner-validated milestones and continued grant selection serve as the primary indicators of execution.

Short descriptiontext

Spark Biopharma is a Seoul-based clinical-stage biotech that discovers first-in-class small-molecule therapeutics using its proprietary phenotypic drug discovery (pDOS) platform, serving pharmaceutical partners across autoimmune, inflammatory, fibrotic, neurodegenerative, and oncology indications through licensing and co-development deals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
phenotypic drug discovery, small molecule therapeutics, fluorescent bioprobe products, target identification platform, biopharmaceutical research services
Industry3 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Drug Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Bioprobe Product Sales
TypeOne Time License
Description

Sale of fluorescent bioprobe products for drug discovery research including GB2-CY3 (GLUT-specific glucose transporter dye) and SF44 (lipid droplet dye)

sparkbiopharma.com
2Research Collaborations and Licensing
TypeLicensing Royalties
Description

Collaborative research agreements with pharmaceutical companies for drug development using proprietary phenotypic discovery technology

linkedin.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1GB2-CY3 - GLUT-specific fluorescent glucose transporter dye
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$450.00 USD per 2mg powder; Store at RT (solid), -20°C (DMSO solution)

sparkbiopharma.com
2SF44 (Seoul-Fluor44) - Lipid droplet visualization and quantification probe
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$450.00 USD per 2mg powder; absorption/emission maxima 445/611 nm; fluorogenic only at LDs, no washing or fixation required

sparkbiopharma.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Spark Biopharma discovers and develops first-in-class small-molecule therapeutics using its proprietary phenotypic drug discovery (pDOS) platform, which integrates Seoul-Fluor fluorescent probes and FITGE/TS-FITGE target identification technologies. The company also commercializes catalog bioprobe research tools (GB2-CY3 and SF44/Seoul-Fluor44) for cellular glucose uptake and lipid droplet imaging, sold directly to researchers through its website.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Series C investment of 250억 원 secured in 2022
+1 more record
Product overview1 text field

Spark Biopharma is a biopharmaceutical company that discovers and develops small-molecule therapeutics using phenotypic discovery technology. The company's core offering consists of its pDOS (phenotypic discovery and optimization system) technology platform for identifying novel first-in-class therapeutics. Additionally, Spark Biopharma commercializes research tools including GB2-CY3 and SF44 (Seoul-Fluor44) fluorescent bioprobes for cellular analysis applications such as glucose uptake measurement and lipid droplet visualization.

Product and service3 records
1GB2-CY3 Bioprobe
CategoryResearch Tools / Fluorescent Bioprobes
Description

A GLUT-specific transportable fluorescent dye for quantitative measurement of glucose uptake in live cells or model organisms without requiring cytosol extraction or radiation; absorption/emission maxima at 545/555 nm; sold at USD 450 per 2mg powder for research use.

2SF44 (Seoul-Fluor44) Bioprobe
CategoryResearch Tools / Fluorescent Bioprobes
Description

A fluorogenic dye for visualization and quantification of cellular lipid droplets in cells, tissues, and model organisms; absorption/emission maxima at 445/611 nm; fluorogenic only at lipid droplets, requiring no washing or fixation steps; sold at USD 450 per 2mg powder for research use.

3pDOS Technology Platform (Phenotypic Drug Discovery)
CategoryDrug Discovery Platform / Licensing and Collaboration
Description

Proprietary phenotypic drug discovery platform integrating molecular diversity creation, disease-mimicking phenotypic screening, Seoul-Fluor fluorescent probes, FITGE/TS-FITGE target identification, and proteomics/biomarker capabilities; licensed to and used with pharmaceutical partners such as Odyssey Therapeutics, LG Chemistry, and HK Inno.N for first-in-class small-molecule therapeutic discovery in autoimmune, inflammatory, fibrotic, Parkinson's disease, dyslipidemia, and oncology indications.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

Collaboration to develop autoimmune and inflammatory disease drugs using the pDOS technology within Odyssey's research strategy. Odyssey recently raised over USD 700 million in funding and aims to diversify its development pipeline with this partnership.

2LG Chemistry
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-30
Description

Joint research and license agreement for next-generation drug discovery using Spark Biopharma's phenotypic discovery platform.

sparkbiopharma.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Partnership for AI-driven antibody-based drug development platform utilizing advanced computational approaches.

4Donga ST (동아에스티)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-11-13
Description

Business partnership agreement signed for collaborative drug development activities.

sparkbiopharma.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-06
Description

Co-development partnership for dyslipidemia drug development using Spark Biopharma's proprietary technology platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Recursion uses high-throughput phenotypic screening combined with AI/ML to discover small-molecule therapeutics, the same core thesis as Spark Biopharma's pDOS platform. Both companies pursue first-in-class drug discovery through image-based, disease-relevant assays and operate similar target-ID workflows.

TypeDirect peer
Description

Evotec operates a discovery and development services platform with deep expertise in phenotypic screening, target identification, and partnered small-molecule R&D for pharma and biotech clients, mirroring Spark's partnership-led business model.

TypeDirect peer
Description

Insitro combines machine learning with phenotypic disease models to discover novel therapeutics, overlapping with Spark's phenotypic screening approach to first-in-class drug discovery and serving similar pharma partnership customers.

TypeDirect peer
Description

Schrödinger operates a computational drug discovery platform that includes physics-based modeling and structure-based design for small-molecule therapeutics. While more computation-led than Spark, both companies pursue first-in-class discovery and license tools/technology to pharma partners.

TypeDirect peer
Description

Cyclerion applies phenotype-driven approaches to small-molecule therapeutic discovery, sharing with Spark Biopharma a focus on novel mechanism, first-in-class candidates and partnered clinical development.

TypeBroad incumbent
Description

WuXi AppTec is a global CRO/CDMO that offers small-molecule drug discovery, target identification, and biologics services to pharma clients. It serves a comparable pharma-partnered discovery customer base as Spark but at vastly greater scale and breadth.

TypeBroad incumbent
Description

Charles River offers drug discovery services including phenotypic screening, medicinal chemistry, and target identification across multiple therapeutic areas. Comparable business model to Spark's pharma-licensed discovery services, but at significantly larger scale and as part of a full CRO portfolio.

TypeBroad incumbent
Description

Eurofins Discovery provides commercial drug discovery services including phenotypic assays, screening libraries, and medicinal chemistry to pharmaceutical and biotech clients. Comparable service offering to Spark's phenotypic discovery platform.

TypeDirect peer
Description

AbCellera operates a technology-platform discovery model (antibody-focused) with deep pharma partnerships for co-development, analogous to Spark's platform-plus-partnerships approach to therapeutic discovery, though focused on antibodies rather than small molecules.

TypeRegional player
Description

Hanmi is a leading South Korean pharmaceutical company pursuing innovative small-molecule and peptide drug development. Comparable Korean-market peer with similar therapeutic area interests (oncology, autoimmune, metabolic) to Spark's pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spark Biopharma

Biopharmaceutical Drug Discoverysparkbiopharma.com

Spark Biopharma is a Seoul-based clinical-stage biotech that discovers first-in-class small-molecule therapeutics using its proprietary phenotypic drug discovery (pDOS) platform, serving pharmaceutical partners across autoimmune, inflammatory, fibrotic, neurodegenerative, and oncology indications through licensing and co-development deals.

What Spark Biopharma does

Spark Biopharma is a Seoul-based, privately held biopharmaceutical company founded in 2016 that discovers and develops first-in-class small-molecule therapeutics using its proprietary phenotypic drug discovery platform (pDOS). The company's discovery stack integrates three core technology layers: pDOS for molecular diversity creation, Seoul-Fluor custom-designed fluorescent probes for visualizing phenotypic changes in cellular systems, and FITGE/TS-FITGE for target identification and mechanism-of-action elucidation through in-gel fluorescence difference via thermal stability shift. Spark targets pharmaceutical and biotech customers developing therapeutics across autoimmune disease, inflammatory disease, fibrosis, Parkinson's disease, dyslipidemia, and cancer, and currently markets two research-use bioprobes — GB2-CY3 (a GLUT-specific glucose transporter dye) and SF44 (a lipid droplet visualization probe) — priced at USD 450 per 2 mg through direct website sales.

The company's business model combines three revenue streams: (i) bioprobe product sales via a direct e-commerce channel, (ii) research collaborations and licensing agreements with pharmaceutical partners including LG Chemistry, Odyssey Therapeutics, HK Inno.N, Handok, and Donga ST, and (iii) non-dilutive grant funding from Korean national programs such as KDDF and the national new drug development project. As of 2026, Spark's pipeline includes SBP-401 (FDA Orphan Drug Designation, February 2024), an HMGB1 inhibitor for idiopathic pulmonary fibrosis (Phase 2, KDDF-selected), SBP-201 for Parkinson's disease (national project-selected, December 2025), and a STING degrader program. The company is led by founder and CEO Park Seung-beom, a Seoul National University Chemistry Department professor, and is actively preparing for a KOSDAQ IPO after completing a KRW 31.5 billion pre-IPO funding round in May 2026.

Spark has raised approximately KRW 28.5 billion across disclosed rounds (Handok KRW 3 billion in November 2021, Series C KRW 25 billion in April 2022) plus the 2026 pre-IPO round, with a syndicate of Korean institutional investors including Korea Development Bank, Industrial Bank of Korea, Shinhan Capital, KB Investment, IMM Investment, and Company K Partners. With 11-50 employees and no public revenue disclosure, the company is in a clinical-stage growth phase where partner-validated milestones and continued grant selection serve as the primary indicators of execution.

Spark Biopharma firmographics

Firmographics
Name
Spark Biopharma
Legal name
SparkBioPharma, INC.
Website
https://sparkbiopharma.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Spark Biopharma is a Seoul-based clinical-stage biotech that discovers first-in-class small-molecule therapeutics using its proprietary phenotypic drug discovery (pDOS) platform, serving pharmaceutical partners across autoimmune, inflammatory, fibrotic, neurodegenerative, and oncology indications through licensing and co-development deals.
Ownership category
akta.pro rank

Spark Biopharma industry classification

Industry
Product category
Biopharmaceutical Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Phenotypic drug discovery
  • Small molecule therapeutics
  • Fluorescent bioprobe products
  • Target identification platform
  • Biopharmaceutical research services

Where Spark Biopharma is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Spark Biopharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Bioprobe Product Sales: Sale of fluorescent bioprobe products for drug discovery research including GB2-CY3 (GLUT-specific glucose transporter dye) and SF44 (lipid droplet dye)
  2. Research Collaborations and Licensing: Collaborative research agreements with pharmaceutical companies for drug development using proprietary phenotypic discovery technology

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goGB2-CY3 - GLUT-specific fluorescent glucose transporter dye
Unit PricingPay-as-you-goSF44 (Seoul-Fluor44) - Lipid droplet visualization and quantification probe

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Spark Biopharma product offering

Product offering

Core offering

Spark Biopharma discovers and develops first-in-class small-molecule therapeutics using its proprietary phenotypic drug discovery (pDOS) platform, which integrates Seoul-Fluor fluorescent probes and FITGE/TS-FITGE target identification technologies. The company also commercializes catalog bioprobe research tools (GB2-CY3 and SF44/Seoul-Fluor44) for cellular glucose uptake and lipid droplet imaging, sold directly to researchers through its website.

Product overview

Spark Biopharma is a biopharmaceutical company that discovers and develops small-molecule therapeutics using phenotypic discovery technology. The company's core offering consists of its pDOS (phenotypic discovery and optimization system) technology platform for identifying novel first-in-class therapeutics. Additionally, Spark Biopharma commercializes research tools including GB2-CY3 and SF44 (Seoul-Fluor44) fluorescent bioprobes for cellular analysis applications such as glucose uptake measurement and lipid droplet visualization.

Differentiator

Problem solved

Functional benefit

Products and services

  • GB2-CY3 Bioprobe A GLUT-specific transportable fluorescent dye for quantitative measurement of glucose uptake in live cells or model organisms without requiring cytosol extraction or radiation; absorption/emission maxima at 545/555 nm; sold at USD 450 per 2mg powder for research use.
  • SF44 (Seoul-Fluor44) Bioprobe A fluorogenic dye for visualization and quantification of cellular lipid droplets in cells, tissues, and model organisms; absorption/emission maxima at 445/611 nm; fluorogenic only at lipid droplets, requiring no washing or fixation steps; sold at USD 450 per 2mg powder for research use.
  • pDOS Technology Platform (Phenotypic Drug Discovery) Proprietary phenotypic drug discovery platform integrating molecular diversity creation, disease-mimicking phenotypic screening, Seoul-Fluor fluorescent probes, FITGE/TS-FITGE target identification, and proteomics/biomarker capabilities; licensed to and used with pharmaceutical partners such as Odyssey Therapeutics, LG Chemistry, and HK Inno.N for first-in-class small-molecule therapeutic discovery in autoimmune, inflammatory, fibrotic, Parkinson's disease, dyslipidemia, and oncology indications.

Quantifiable outcome

  • Series C investment of 250억 원 secured in 2022
  • +1 more outcomes

Companies that use Spark Biopharma

Customer profile

Segments1 record

Ideal customer profiles2 records

Spark Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Spark Biopharma partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Odyssey TherapeuticscoreStrategic or Co-development Partner · 29 September 2025Collaboration to develop autoimmune and inflammatory disease drugs using the pDOS technology within Odyssey's research strategy. Odyssey recently raised over USD 700 million in funding and aims to diversify its development pipeline with this partnership.
  • LG ChemistrycoreStrategic or Co-development Partner · 30 June 2025Joint research and license agreement for next-generation drug discovery using Spark Biopharma's phenotypic discovery platform.
  • PharmAbcineminorStrategic or Co-development Partner · 1 January 2025Partnership for AI-driven antibody-based drug development platform utilizing advanced computational approaches.
  • Donga ST (동아에스티)minorStrategic or Co-development Partner · 13 November 2024Business partnership agreement signed for collaborative drug development activities.
  • HK Inno.NcoreStrategic or Co-development Partner · 6 September 2023Co-development partnership for dyslipidemia drug development using Spark Biopharma's proprietary technology platform.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Spark Biopharma competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Recursion uses high-throughput phenotypic screening combined with AI/ML to discover small-molecule therapeutics, the same core thesis as Spark Biopharma's pDOS platform. Both companies pursue first-in-class drug discovery through image-based, disease-relevant assays and operate similar target-ID workflows.
  • Evotec SE: Evotec operates a discovery and development services platform with deep expertise in phenotypic screening, target identification, and partnered small-molecule R&D for pharma and biotech clients, mirroring Spark's partnership-led business model.
  • Insitro: Insitro combines machine learning with phenotypic disease models to discover novel therapeutics, overlapping with Spark's phenotypic screening approach to first-in-class drug discovery and serving similar pharma partnership customers.
  • Schrödinger, Inc. Schrödinger operates a computational drug discovery platform that includes physics-based modeling and structure-based design for small-molecule therapeutics. While more computation-led than Spark, both companies pursue first-in-class discovery and license tools/technology to pharma partners.
  • Cyclerion Therapeutics: Cyclerion applies phenotype-driven approaches to small-molecule therapeutic discovery, sharing with Spark Biopharma a focus on novel mechanism, first-in-class candidates and partnered clinical development.
  • AbCellera Biologics: AbCellera operates a technology-platform discovery model (antibody-focused) with deep pharma partnerships for co-development, analogous to Spark's platform-plus-partnerships approach to therapeutic discovery, though focused on antibodies rather than small molecules.

Broad incumbents

  • WuXi AppTec: WuXi AppTec is a global CRO/CDMO that offers small-molecule drug discovery, target identification, and biologics services to pharma clients. It serves a comparable pharma-partnered discovery customer base as Spark but at vastly greater scale and breadth.
  • Charles River Laboratories: Charles River offers drug discovery services including phenotypic screening, medicinal chemistry, and target identification across multiple therapeutic areas. Comparable business model to Spark's pharma-licensed discovery services, but at significantly larger scale and as part of a full CRO portfolio.
  • Eurofins Discovery: Eurofins Discovery provides commercial drug discovery services including phenotypic assays, screening libraries, and medicinal chemistry to pharmaceutical and biotech clients. Comparable service offering to Spark's phenotypic discovery platform.

Regional players

  • Hanmi Pharmaceutical: Hanmi is a leading South Korean pharmaceutical company pursuing innovative small-molecule and peptide drug development. Comparable Korean-market peer with similar therapeutic area interests (oncology, autoimmune, metabolic) to Spark's pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Spark Biopharma social profiles

Digital presence

Spark Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spark Biopharma leadership team

Management profile

Number of profiles

Profiles1 record

Spark Biopharma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spark Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spark Biopharma

What does Spark Biopharma do?

Spark Biopharma discovers and develops first-in-class small-molecule therapeutics using its proprietary phenotypic drug discovery (pDOS) platform, which integrates Seoul-Fluor fluorescent probes and FITGE/TS-FITGE target identification technologies. The company also commercializes catalog bioprobe research tools (GB2-CY3 and SF44/Seoul-Fluor44) for cellular glucose uptake and lipid droplet imaging, sold directly to researchers through its website.

Is Spark Biopharma a public or private company?

Spark Biopharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Spark Biopharma founded?

Spark Biopharma was founded in 2016. It employs 11 to 50 people.

Where is Spark Biopharma based?

Spark Biopharma is headquartered in Seoul, South Korea, in the Asia region.

How does Spark Biopharma make money?

Two revenue lines are on record. Bioprobe Product Sales are the primary driver. The others are research Collaborations and Licensing.

Who are Spark Biopharma's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Evotec SE, Insitro, Schrödinger, Inc., Cyclerion Therapeutics and AbCellera Biologics. Broad incumbents are WuXi AppTec, Charles River Laboratories and Eurofins Discovery. Hanmi Pharmaceutical is listed as a regional player.

Does Spark Biopharma have an API?

No public API is recorded for Spark Biopharma.

What industry is Spark Biopharma in?

Spark Biopharma's product category is Biopharmaceutical Drug Discovery. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals